In PSC with colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment. (Q51165355)

31 March 2018

title

In PSC with colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment. (English)

1 reference

31 March 2018

author name string

G Rudolph

1

1 reference

31 March 2018

D N Gotthardt

2

1 reference

31 March 2018

P Kloeters-Plachky

3

1 reference

31 March 2018

H Kulaksiz

4

1 reference

31 March 2018

P Schirmacher

5

1 reference

31 March 2018

A Stiehl

6

1 reference

31 March 2018

publication date

9 June 2011

1 reference

31 March 2018

Digestive Diseases and Sciences

published in

1 reference

31 March 2018

volume

56

1 reference

31 March 2018

issue

12

1 reference

31 March 2018

page(s)

3624-3630

1 reference

31 March 2018

https://scigraph.springernature.com/pub.10.1007/s10620-011-1763-2

exact match

0 references

cites work

High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective

1 reference

12 December 2020

Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment

1 reference

12 December 2020

Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential

1 reference

12 December 2020

The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid.

1 reference

12 December 2020

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

1 reference

12 December 2020

Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis

1 reference

12 December 2020

Acute effects of ursodeoxycholic and chenodeoxycholic acid on the small intestinal absorption of bile acids

1 reference

12 December 2020

Transformation of chenodeoxycholic acid and ursodeoxycholic acid by human intestinal bacteria

1 reference

12 December 2020

Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy.

1 reference

12 December 2020

Primary sclerosing cholangitis

1 reference

12 December 2020

Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis

1 reference

12 December 2020

Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment

1 reference

12 December 2020

Primary sclerosing cholangitis: the role of endoscopic therapy

1 reference

12 December 2020

Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis.

1 reference

12 December 2020

Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis

1 reference

12 December 2020

The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis

1 reference

12 December 2020

High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis

1 reference

12 December 2020

Primary Sclerosing Cholangitis, Inflammatory Bowel Disease, and Colon Cancer

1 reference

12 December 2020

Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis

1 reference

12 December 2020

Colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

1 reference

12 December 2020

Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group

1 reference

12 December 2020

Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study

1 reference

12 December 2020

Endoscopic retrograde cholangiopancreatography in diagnosis and treatment of primary sclerosing cholangitis

1 reference

12 December 2020

High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

1 reference

12 December 2020

High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study

1 reference

12 December 2020

Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment

1 reference

12 December 2020

High lifetime risk of cancer in primary sclerosing cholangitis

1 reference

12 December 2020

Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis

1 reference

12 December 2020

Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period

1 reference

12 December 2020

A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis

1 reference

12 December 2020

In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival

1 reference

12 December 2020

Natural history and prognostic variables in primary sclerosing cholangitis

1 reference

12 December 2020

Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study.

1 reference

12 December 2020

Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial

1 reference

12 December 2020

Biliary candida infections in primary sclerosing cholangitis

1 reference

12 December 2020

Risk of colorectal neoplasia in patients with primary sclerosing cholangitis.

1 reference

12 December 2020

Metabolism in man of 7-ketolithocholic acid: precursor of cheno- and ursodeoxycholic acids

1 reference

12 December 2020

Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis

1 reference

12 December 2020

Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

1 reference

12 December 2020

Clinicopathologic features of the syndrome of primary sclerosing cholangitis

1 reference

12 December 2020

Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology

1 reference

12 December 2020

Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid.

1 reference

12 December 2020

Ursodeoxycholic acid inhibits Ras mutations, wild-type Ras activation, and cyclooxygenase-2 expression in colon cancer.

1 reference

12 December 2020

Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study

1 reference

12 December 2020

10.1007/S10620-011-1763-2

Identifiers

DOI

1 reference

31 March 2018

PubMed ID

21656181

1 reference

31 March 2018